Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204637 | 0.97 | CYP4F2 (0.50) | CYP4F2CYP4A11MGLLBCHETDP1 | |
| SCHEMBL2208231 | 0.96 | TDP1 (0.51) | CYP4F2CYP4A11MGLLBCHETDP1 | |
| SCHEMBL2208778 | 0.94 | CYP4F2 (0.50) | CYP4F2CYP4A11MGLLBCHETDP1 | |
| SCHEMBL3926767 | 0.87 | MAOB (0.50) | CYP4F2CYP4A11BCHEMAOB | |
| SCHEMBL29818997 | 0.87 | TAAR1 (0.55) | CYP4F2CYP4A11BCHEMAOBTAAR1 | |
| SCHEMBL2204444 | 0.87 | TAAR1 (0.55) | CYP4F2CYP4A11BCHEMAOBTAAR1 | |
| SCHEMBL20332570 | 0.86 | KCNA3 (0.53) | CYP4F2CYP4A11KCNH2TAAR1 | |
| SCHEMBL2207165 | 0.86 | MAOA (0.53) | CYP4F2CYP4A11BCHEMAOBKCNH2 | |
| SCHEMBL2206195 | 0.86 | CYP4F2 (0.66) | CYP4F2CYP4A11MGLLBCHEMAOB | |
| SCHEMBL4568879 | 0.86 | PPARA (0.52) | CYP4F2CYP4A11MGLLBCHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CYP4F2 4314/4885CYP4A11 1054/4885MGLL 1007/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885MGLL 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.